Pancreas cancer project
Registry on resectable or potentially resectable exocrine pancreatic cancer: « PANCREAS-CGE » Registry
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable
The research project on pancreatic cancer has come from a bottom/up approach; the Cancéropôle asked its territories advisors to organize meetings and consultations around digestive tract cancer. After a thorough analysis and a final meeting with the Cancéropôle board it appeared that a pancreatic cancer registry would benefit and federate research teams. It was decided to focus the study on resectable or potentially resectable exocrine pancreatic cancer. The follow-up of the patients and the quality of the samples would be guaranteed by the Cancéropôle.
Several work-groups were put into place in order to define the variables for the registry. The registry will include plasma and tumor samples, a detailed and up to date clinical review and quality of life questionnaire. Assessment of the biological samples and a review of clinical entries will be performed to ensure that the data are of high quality. This will allow the use of the registry for highly relevant and excellent research programs.
Ancillary studies can be associated to the registry. They can be submitted to the scientific board of the registry via a form (under development).
The registry has been approved by the ethical committee as well as the French agency of drug safety, in spring 2016. Inclusions of patients began in July 2016.
After 3 years of operation and more than 115 patients included (June 2019), the protocol was extended by 3 years to reach the 350 patients required for the primary and secondary objectives analyzes.
This research project could not have taken place without the strong support of our 2 Regions: Grand Est and Bourgogne-Franche-Comté.